Literature DB >> 20348528

A case of yellow fever vaccine-associated viscerotropic disease in Ecuador.

Richard W Douce1, Diana Freire, Betzabe Tello, Gavino A Vásquez.   

Abstract

We report the first case of viscerotropic syndrome in Ecuador. Because of similarities between yellow fever and viscerotropic syndrome, the incidence of this recently described complication of vaccination with the 17D yellow fever vaccine is not known. There is a large population in South America that is considered at risk for possible reemergence of urban yellow fever. Knowledge of potentially fatal complications of yellow fever vaccine should temper decisions to vaccinate populations where the disease is not endemic.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20348528      PMCID: PMC2844553          DOI: 10.4269/ajtmh.2010.09-0570

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  13 in total

Review 1.  Prevention of yellow fever in persons traveling to the tropics.

Authors:  Thomas P Monath; Martin S Cetron
Journal:  Clin Infect Dis       Date:  2002-04-25       Impact factor: 9.079

2.  Adverse events associated with 17D-derived yellow fever vaccination--United States, 2001-2002.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2002-11-08       Impact factor: 17.586

3.  Dengue and yellow fever--challenges for the development and use of vaccines.

Authors:  Thomas P Monath
Journal:  N Engl J Med       Date:  2007-11-29       Impact factor: 91.245

4.  Characterization of a viscerotropic yellow fever vaccine variant from a patient in Brazil.

Authors:  Amber R Engel; Pedro F C Vasconcelos; Monica A McArthur; Alan D T Barrett
Journal:  Vaccine       Date:  2006-01-18       Impact factor: 3.641

5.  The revised International Health Regulations (2005): impact on yellow fever vaccination in clinical practice.

Authors:  Annelies Wilder-Smith; David R Hill; David O Freedman
Journal:  Am J Trop Med Hyg       Date:  2008-03       Impact factor: 2.345

Review 6.  Yellow fever-associated viscerotropic disease in Barcelona, Spain.

Authors:  Jose Muñoz; Anna Vilella; Cristina Domingo; Josep Maria Nicolas; Fernando de Ory; Manuel Corachan; Antonio Tenorio; Joaquim Gascon
Journal:  J Travel Med       Date:  2008 May-Jun       Impact factor: 8.490

7.  Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases.

Authors:  M Martin; T F Tsai; B Cropp; G J Chang; D A Holmes; J Tseng; W Shieh; S R Zaki; I Al-Sanouri; A F Cutrona; G Ray; L H Weld; M S Cetron
Journal:  Lancet       Date:  2001-07-14       Impact factor: 79.321

Review 8.  West Nile virus.

Authors:  Laura D Kramer; Jun Li; Pei-Yong Shi
Journal:  Lancet Neurol       Date:  2007-02       Impact factor: 44.182

9.  Advanced age a risk factor for illness temporally associated with yellow fever vaccination.

Authors:  M Martin; L H Weld; T F Tsai; G T Mootrey; R T Chen; M Niu; M S Cetron
Journal:  Emerg Infect Dis       Date:  2001 Nov-Dec       Impact factor: 6.883

10.  Viscerotropic disease following yellow fever vaccination in Peru.

Authors:  Alvaro Whittembury; Gladys Ramirez; Herminio Hernández; Alba Maria Ropero; Steve Waterman; María Ticona; Margo Brinton; Jorge Uchuya; Mark Gershman; Washington Toledo; Erin Staples; Clarense Campos; Mario Martínez; Gwong-Jen J Chang; Cesar Cabezas; Robert Lanciotti; Sherif Zaki; Joel M Montgomery; Thomas Monath; Edward Hayes
Journal:  Vaccine       Date:  2009-08-11       Impact factor: 3.641

View more
  4 in total

1.  High-throughput multiplexed xMAP Luminex array panel for detection of twenty two medically important mosquito-borne arboviruses based on innovations in synthetic biology.

Authors:  Lyudmyla G Glushakova; Andrea Bradley; Kevin M Bradley; Barry W Alto; Shuichi Hoshika; Daniel Hutter; Nidhi Sharma; Zunyi Yang; Myong-Jung Kim; Steven A Benner
Journal:  J Virol Methods       Date:  2015-02-11       Impact factor: 2.014

2.  Viscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data.

Authors:  Mark D Gershman; J Erin Staples; Adwoa D Bentsi-Enchill; J Gabrielle Breugelmans; Glacus S Brito; Luiz Antonio Bastos Camacho; Pascale Cottin; Cristina Domingo; Anna Durbin; Joaquim Gascon; Fouzia Guenaneche; Edward B Hayes; Zsuzsanna Jelenik; Alena Khromava; Reinaldo de Menezes Martins; Mario Masana Wilson; Nathalie Massy; Abdulsalami Nasidi; Matthias Niedrig; Adam Sherwat; Theodore Tsai; Anna Vilella; Mary Elizabeth Wilson; Katrin S Kohl
Journal:  Vaccine       Date:  2012-05-04       Impact factor: 3.641

Review 3.  Yellow fever vaccine-associated viscerotropic disease: current perspectives.

Authors:  Roger E Thomas
Journal:  Drug Des Devel Ther       Date:  2016-10-12       Impact factor: 4.162

4.  Viscerotropic disease and acute uveitis following yellow fever vaccination: a case report.

Authors:  Lev Volkov; Gilda Grard; Pierre-Edouard Bollaert; Guillaume A Durand; Aurélie Cravoisy; Marie Conrad; Lionel Nace; Guilhem Courte; Rémy Marnai; Isabelle Leparc-Goffart; Sébastien Gibot
Journal:  BMC Infect Dis       Date:  2020-02-10       Impact factor: 3.090

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.